Capnia (SLNO) Given a $4.00 Price Target at Maxim Group

Capnia (NASDAQ:SLNO) has been assigned a $4.00 price objective by stock analysts at Maxim Group in a research note issued on Monday. The brokerage presently has a “buy” rating on the stock. Maxim Group’s target price would suggest a potential upside of 138.10% from the company’s current price.

Separately, ValuEngine raised shares of Capnia from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.

Shares of SLNO traded down $0.13 during mid-day trading on Monday, hitting $1.68. The company had a trading volume of 32,188 shares, compared to its average volume of 60,496. Capnia has a 1-year low of $1.32 and a 1-year high of $3.75.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Birchview Capital LP acquired a new position in shares of Capnia during the fourth quarter worth $1,032,000. 683 Capital Management LLC lifted its position in shares of Capnia by 462.7% during the fourth quarter. 683 Capital Management LLC now owns 844,112 shares of the company’s stock worth $1,519,000 after purchasing an additional 694,112 shares in the last quarter. Finally, Sabby Management LLC acquired a new position in shares of Capnia during the fourth quarter worth $1,647,000. 46.56% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Capnia (SLNO) Given a $4.00 Price Target at Maxim Group” was originally posted by Enterprise Leader and is owned by of Enterprise Leader. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at

Capnia Company Profile

Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, diazoxide choline controlled-release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into Phase II/III clinical development.

Receive News & Ratings for Capnia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capnia and related companies with's FREE daily email newsletter.

Leave a Reply